Bookbuilding IPO | ₹30 Cr | Listed at NSE SME | Wed, May 14, 2025 - Fri, May 16, 2025
Accretion Pharmaceuticals IPO is a book build issue of ₹29.75 crores. The issue is entirely a fresh issue of 0.29 crore shares of ₹29.75 crore.
Accretion Pharmaceuticals IPO bidding started from May 14, 2025 and ended on May 16, 2025. The allotment for Accretion Pharmaceuticals IPO was finalized on May 19, 2025. The shares got listed on NSE SME on May 21, 2025.
Accretion Pharmaceuticals IPO price band is set at ₹101 per share. The lot size for an application is 1,200. The minimum amount of investment required by an retail is ₹1,21,200 (1200 shares) (based on upper price). The minimum lot size for investment in HNI is 2 lots (2,400 shares), amounting to ₹2,42,400.
Jawa Capital Services Pvt.Ltd. was the book running lead manager and Kfin Technologies Ltd. was the registrar of the issue. The Market Maker of the company is Gretex Share Broking Pvt.Ltd..
Refer to Accretion Pharmaceuticals IPO RHP for detailed Information.
IPO Open
Wed, May 14, 2025
IPO Close
Fri, May 16, 2025
Issue Price
₹101 per share
Market Cap (Pre-IPO)
₹112.27 Cr
| IPO Date | 14 to 16 May, 2025 |
| Listed on | Wed, May 21, 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹96 to ₹101 |
| Issue Price | ₹101 per share |
| Lot Size | 1,200 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 29,46,000 shares (agg. up to ₹30 Cr) |
| Reserved for Market Maker | 1,47,600 shares Gretex Share Broking Pvt.Ltd. (agg. up to ₹1 Cr) |
| Fresh Issue (Ex Market Maker) | 27,98,400 shares (agg. up to ₹28 Cr) |
| Net Offered to Public | 27,98,400 shares (agg. up to ₹28 Cr) |
| Share Holding Pre Issue | 81,70,000 shares |
| Share Holding Post Issue | 1,11,16,000 shares |
| NSE Symbol | ACCPL |
| ISIN | INE0T8T01010 |
Accretion Pharmaceuticals IPO comprises a total issue size of 29,46,000 shares. The net offer to the public is 27,98,400 shares, after excluding 1,47,600 shares allotted on a firm basis. Of the Net offer 3,52,800 (12.61%) are allocated to QIB, 12,22,800 (43.70%) allocated to NII 12,22,800 (43.70%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 3,52,800 | 12.61% | 11.98% |
| − Anchor Investor Shares Offered | 2,11,200 | 7.17% | |
| − QIB (Ex. Anchor) Shares Offered | 1,41,600 | 4.81% | |
| NII (HNI) Shares Offered | 12,22,800 | 43.70% | 41.51% |
| Retail Shares Offered | 12,22,800 | 43.70% | 41.51% |
| Firm Reservations | |||
| Market Maker Shares Offered | 1,47,600 | 5.01% | |
| Total Shares Offered | 29,46,000 | 100.00% | 100.00% |
Investors can bid for a minimum of 1,200 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1,200 | ₹1,21,200 |
| Retail (Max) | 1 | 1,200 | ₹1,21,200 |
| HNI (Min) | 2 | 2,400 | ₹2,42,400 |
Accretion Pharmaceuticals IPO raises ₹2.13 crore from anchor investors. Accretion Pharmaceuticals IPO Anchor bid date is May 13, 2025.
📝 Anchor Investors Letter (PDF)
| Bid Date | Tue, May 13, 2025 |
| Shares Offered | 2,11,200 |
| Anchor Portion (₹ Cr.) | 2.13 |
| Anchor lock-in period end date for 50% shares (30 Days) | Wed, Jun 18, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | Sun, Aug 17, 2025 |
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.
The company also offers contract manufacturing services. The Company manufactures and markets Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup).
The company also holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications, reflecting its dedication to quality and environmental management systems.
The company's manufacturing unit is located in Ahmedabad, Sanand, Gujarat.
The company has expanded its global footprint, marking its presence in more than 20 countries, including regions in Africa, Southeast Asia, and the Middle East.
Product Portfolio and Services
As of January 2025, the company has 83 employees (including 4 Executive Directors) on its payroll.
Competitive Strength:
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 39.99 | 27.05 | 20.58 | 17.74 |
| Total Income | 35.75 | 33.94 | 29.53 | 22.58 |
| Profit After Tax | 5.24 | 3.88 | 0.10 | 0.08 |
| NET Worth | 13.58 | 5.35 | 3.84 | 3.08 |
| Reserves and Surplus | 5.41 | 1.35 | ||
| Total Borrowing | 13.79 | 13.48 | 8.47 | 7.61 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capital expenditure towards purchase of new equipment/ machineries, etc. | 2.70 |
| 2 | Capital expenditure towards upgradation of existing manufacturing facility | 4.66 |
| 3 | Repayment/prepayme nt of certain borrowings availed by the Company | 0.99 |
| 4 | Funding working capital requirements | 14.68 |
| 5 | General Corporate Purpose | 4.43 |
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 72.47% |
| ROCE | 36.73% |
| Debt/Equity | 2.52 |
| RoNW | 72.47% |
| PAT Margin | 11.51% |
| Price to Book Value | 7.55 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 4.74 | 6.28 |
| P/E (x) | 21.29 | 16.08 |
| Promoter Holding | 100% | 73.48% |
| Market Cap | ₹112.27 Cr. |
The Accretion Pharmaceuticals IPO is subscribed 7.67 times on May 16, 2025 6:19:58 PM (Day 3). The public issue subscribed 10.54 times in the retail category, 12.14 times in the QIB category, and 4.28 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for | Total Application |
|---|---|---|---|---|
| QIB | 12.14 | 1,41,600 | 17,19,600 | 4 |
| NII* | 4.28 | 12,22,800 | 52,36,800 | 887 |
| Retail | 10.54 | 12,22,800 | 1,28,85,600 | 10,738 |
| Total | 7.67 | 25,87,200 | 1,98,42,000 | 11,629 |
Total Application : 11,629
*Market Maker portion is not included to NII/HNI.
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Lead manager(s) fees including underwriting commission, Legal Advisor and Advisor to the issue consultancy fees | 1.69 |
| 2 | Brokerage, selling commission and upload fees including Market maker | 0.16 |
| 3 | Registrars to the issue | 0.01 |
| 4 | Advertising and marketing expenses | 0.30 |
| 5 | Regulators including stock exchanges | 0.10 |
| 6 | Printing and distribution of issue stationary | 0.02 |
| 7 | Restatement of Accounts and Peer Review Auditor | 0.03 |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹101.00 |
| Open | ₹79.00 |
| Low | ₹75.05 |
| High | ₹82.95 |
| Last Trade | ₹82.95 |
Lead Manager Reports
Accretion Pharmaceuticals IPO is a SME IPO of 29,46,000 equity shares of the face value of ₹10 aggregating up to ₹30 Crores. The issue is priced at ₹101 per share. The minimum order quantity is 1200.
The IPO opens on Wed, May 14, 2025, and closes on Fri, May 16, 2025.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Accretion Pharmaceuticals IPO using UPI as a payment gateway. Zerodha customers can apply in Accretion Pharmaceuticals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Accretion Pharmaceuticals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Accretion Pharmaceuticals IPO opens on Wed, May 14, 2025 and closes on Fri, May 16, 2025.
Accretion Pharmaceuticals IPO lot size is 1200, and the minimum amount required for application is ₹1,21,200.
You can apply in Accretion Pharmaceuticals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Accretion Pharmaceuticals IPO will be done on Monday, May 19, 2025, and the allotted shares will be credited to your demat account by Tue, May 20, 2025. Check the Accretion Pharmaceuticals IPO allotment status.
The Accretion Pharmaceuticals IPO listing date is on Wed, May 21, 2025.
